CRIS100
Phase 1Small molecule
CRIS100 is one of 44 small molecule programs targeting Spinal Cord Injury. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
190 competitors in Spinal Cord Injury
#DrugCompanyPhaseTrials
1Medrol
PfizerPhase 3
Proamatine
TakedaPhase 3
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Minocin
TTriax
Phase 3
Cesamet
BBausch Health Americas, Inc.
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Genotropin
EMD SeronoPhase 3
Myrbetriq
AstellasPhase 2
Gleevec
NovartisPhase 2
Fampridine-SR
AAcorda Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CRIS100. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details